Orlistat-Acrihin, 120 mg capsules 84 pcs

Orlistat refers to specific inhibitors of long-acting gastrointestinal lipases. This substance shows its effect in the lumen of the stomach and small intestine by forming a covalent bond with the active serine center of gastric and pancreatic lipases. As a result of the effect of hypolipidemic agent inactivated enzyme loses the ability to break down fats coming with food in the form of triglycerides (TG) to monoglycerides and absorbable free fatty acids.

Since unreplenished TGs are not absorbed from the gastrointestinal tract (GIT), fewer calories are fed into the body and, as a result, body weight is reduced. Thus, the therapeutic effect of the drug is carried out without its absorption into the systemic bloodstream. Due to the activity of orlistat 24-48 hours after oral administration of the drug, the concentration of fat in stools increases.

Leading to a decrease in fat depot, Orlistat-Acrichin provides effective body weight control. In clinical studies involving obese patients, more pronounced weight loss was observed in the group of patients receiving Orlistat compared to patients on diet therapy alone. Weight loss was already observed within the first 2 weeks of starting Orlistat-Acrychin and for 6-12 months thereafter, even if there was a negative response to diet therapy.

Statistically significant significant improvement in the profile of obesity-related metabolic risk factors was recorded for two years. In addition, there was a significant reduction in body fat deposits when compared to the placebo group. Orlistat such patients were found to have a significant improvement in glycemic control. Also during the use of Orlistat-Acrihin a decrease in doses of antidiabetic drugs, insulin concentration, as well as a decrease in insulin resistance was observed. According to 4-year studies, orlistat therapy was found to significantly reduce the threat of type 2 diabetes, by an average of 37% compared to placebo use. This threat was reduced by about 45% in patients with initial impaired glucose tolerance.

In the group receiving Orlistat, there was a greater reduction in body weight compared with the placebo group, and in addition, a significant improvement in the profile of metabolic risk factors. The new body weight level achieved was maintained for all 4 years of the study. In adolescents with obesity in a 1-year study during treatment with orlistat a decrease in body mass index (BMI) was registered, as well as a decrease in fat deposits and waist and hip circumference compared to the placebo group. Also during the period of taking Orlistat-Acrychin a significant decrease in diastolic blood pressure (BP) was observed in adolescents compared to those who received placebo.

Indications

Orlistat-Acrichin is recommended for long-term therapy in obese patients with BMI ≥ 30 kg/m² or in overweight patients with BMI ≥ 28 kg/m² who have obesity-related risk factors on a moderately restricted low-calorie diet.

Also Orlistat-Acrychin is indicated for administration in patients with type 2 diabetes mellitus with excess body weight or obesity in combination with moderately restricted hypocaloric diet and/or hypoglycemic drugs (insulin and/or sulfonylurea derivatives, metformin).

Active ingredient

Composition

Interaction

Directions for use

Special Instructions

Synopsis

Features

Contraindications

Side effects

Overdose

Similarities